These data collectively demonstrate the specificity of the MIL-38-CD3 BiTE and reliance on the recognition of GPC-1 and MIL-38-CD3 binding for activity and demonstrate the efficacy of MIL-38-CD3 in two phenotypically and clinically distinct prostate cancer cell lines. This evidence concerns the gene GPC1 and prostate cancer.